Biomedical Engineering Reference
In-Depth Information
S. No.
Developer/
Partner
Reference
Product
Details
Clinical
Status as on
Dec. 2009
Drug Target
Indication
Route of
Delivery
Delivery System
ISIS 113715
Phase I
Protein tyrosine
phosphatase 1B
Type 2 diabetes
mellitus
Subcutaneous
injection
Phosphothiorate
AS ODN
ISIS 3521
Phase II
Pkc-Alpha
Metastatic breast
cancer
Intravenous
infusion
Phosphothiorate
AS ODN
ISIS 5132
Phase II
C-Raf kinase
Metastatic breast
cancer
Intravenous
infusion
Phosphothiorate
AS ODN
Alicaforsen
(ISIS 2302)
Phase III
ICAM-1
Crohn's disease
Not available
Phosphothiorate
AS ODN
ISIS-CRP
Rx
Phase I
CRP
Cardiovascular
Not available
Phosphothiorate
AS ODN
ISIS-SGLT2
Rx
Phase I
SGLT2
Type 2 diabetes
Not available
Phosphothiorate
AS ODN
4.
Enzon
Pharmaceuticals,
Inc
http://
www
.enzon.com
EZN-2968
Phase I
anti-HIF-1
LNA
Carcinoma,
lymphoma
Intravenous
LNA AS ODN
5.
Genta
Incorporated
http://
www
.genta.com
Genasense
(G3139,
Oblimerson
sodium)
Phase III
Bcl2
Solid tumors
Subcutaneous/
intravenous
infusion
Phosphothiorate
AS ODN
Inex/Genta
G4460/LR
3001
Phase II
C-myb
Cancer
Intravenous
infusion
Phosphothiorate
AS ODN
6.
Lorus
Therapeutics
http://
www
.lorusthera.com
GTI-2040
Phase I/II
R2
component of
ribonucleotide
reductase (RNR)
Renal cell
carcinoma
Intravenous
Phosphothiorate
AS ODN
GTI-2501
Phase I/II
R1
component of
ribonucleotide
Cancer
Intravenous
Phosphothiorate
AS ODN
Search WWH ::
Custom Search